NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Paradigm Therapeutics, Inc.

Paradigm Therapeutics, Inc.

Private
Mount Pleasant, South CarolinaHealthcare & Life Scienceshttps://www.paradigmtherapeutics.com/

Last Round

VC Round

Jun 18, 2025

Company Overview

Paradigm Therapeutics, Inc. is a biopharmaceutical company that develops innovative topical therapies for the treatment of rare diseases, specifically Epidermolysis Bullosa.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologydrug discoverybiopharmarare diseaseclinical-stagetherapeutic developmentorphan drugepidermolysis bullosadrug pipelineintellectual property licensingresearch collaborationbiotech startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Paradigm Therapeutics, Inc. Comparables

Compare Paradigm Therapeutics, Inc. with similar companies based on industry and business-model similarity.

Paradigm Therapeutics, Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Mariposa Therapeutics
43%
Aegle Therapeutics Corp
38%

Paradigm Therapeutics, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundJun 18, 2025
VC RoundMay 6, 2025

Key People

Founding team and executive leadership

Robert Ryan

Founder And Chief Executive Officer

Founding Team

Paradigm Therapeutics, Inc. Investors

Notable investors and investment history

Paradigm Therapeutics, Inc. investors
InvestorRounds
Eshelman VenturesVC Round

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 18, 2025

    $13M round led by Eshelman Ventures.

  • May 6, 2025

    $13M round led by Eshelman Ventures

Paradigm Therapeutics, Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Paradigm Therapeutics, Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Paradigm Therapeutics, Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersMount Pleasant, South Carolina
Employee Range5
Year Founded2023
Last FundingJun 18, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.